Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil: A Case Report

Abstract

Inhaled treprostinil is the first-choice drug for the treatment of Group 3 pulmonary hypertension (PH) associated with chronic lung disease. A 72-year-old man was diagnosed with interstitial pneumonia, and his respiratory symptoms had gradually worsened. Echocardiography revealed a maximum tricuspid regurgitation pressure gradient (TRPG) of 64 mmHg, and the patient was diagnosed with group 3 PH. Subsequently, he was admitted to the hospital with acute heart failure. Inhaled treprostinil was prescribed, his B-type natriuretic peptide level and maximum TRPG subsequently improved, and his oxygen requirement decreased. Treprostinil inhalation may be effective in treating patients with severe respiratory symptoms of interstitial pneumonia.